Catailyst

Catailyst has combined automation and artificial intelligence to understand scientific, clinical, and business announcements from various public information sources, such as press releases, SEC filings, and trial registrations to create actionable and searchable data points.

Catailyst has launched a database and data analytics platform to provide access to financial, clinical, scientific, and regulatory information exclusively for the life science industry. The company has also developed several real-time alerts using proprietary data science methods of artificial intelligence and natural language processing. The company has applied for patents for its AI technology but no patents have been granted yet. The global life science analytics market was valued at $9.0bn in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.6% from 2023 to 2030. The company does not have many competitors. Catailyst current and future customers are generally categorized into three major categories: the Biotech and Pharma industry, consultants, and investment bankers. Catailyst is currently offering two products. SAAS monthly subscriptions to the database and daily/weekly customizable alerts in a B2B business model. The basic model is priced at $2000/month and the pro model is priced at $3000/month. 

For the year ended December 31, 2022, the Company generated $25,500 in revenues. It has a gross profit of 83%. The company has not officially launched its product yet. 

 

The company plans to use the proceeds for salaries, advertising and marketing, patents, legal and professional services, R&D, technology, website, insurance, and platform fees.

Jit Basak, President, CEO
Previously, Jit was a Transaction Lead of Corporate Development at Shire/Takeda; Inotek Pharmaceutical following Investment Banking Advisory roles. He was a FINRA-registered investment banker and has led transactional work with increasing responsibilities at Ferghana Partners and Capstone-Headwaters. Earlier in his career, Jit spent nine years as a medicinal chemist in multiple therapeutic areas at both midsize biotech and large pharmaceutical companies: Chemocentryx, Inc. and Pfizer, Inc. After completing his post-doctoral research at the University of Chicago, he received his MBA from the University of Connecticut School of Business in finance and international business. Jit holds a Ph.D. from the University of Illinois at Chicago in synthetic organic chemistry and a master’s in chemistry from the Indian Institute of Technology Kanpur, India. He is a first time founder and works full time with the company. 

Sandipan Chattopadhyay, CTO
Sandipan Chattopadhyay, aged 49 years, is the Managing Director and CEO of Xelpmoc. He holds a degree of Bachelor of Statistics (Honors) from the Indian Statistical Institute, Calcutta. He also holds a Post Graduate Diploma in Computer Aided Management from the Indian Institute of Management, Kolkata. He is primarily responsible for the performance and supervision of technical, administrative, and day-to-day operations of developing strategic plans, revenue promotion, profitability, and growth of Xelpmoc. He has more than 24 years of experience in the field of technology. Prior to joining Xelpmoc, he served as the Chief Technical Officer at Just Dial Limited. He has been a Director on Xelpmoc Board since incorporation. He is a first time founder and works part-time for the company. 

The company has a very strong technical and management team.